Explore current trends in cancer with leaders and innovators in Paris, this July 1-2,2020. Schedule is more packed than ever before with exceptional lectures & sessions. Abstract Submission slots are open. Grab your slots now, PS: https://cancer.cmesociety.com/abstract-submission
Theme: Innovations in Cancer Research
Date: May 19- 20, 2020
Conference Venue: London, UK
Showing posts with label oncology conference. Show all posts
Showing posts with label oncology conference. Show all posts
Thursday, March 19, 2020
Saturday, March 7, 2020
Tongue Cancer
Cancer can develop in two different areas of the tongue. Tongue cancer develops at the front of the tongue, while cancer at the back of the tongue is known as oropharyngeal cancer.
Symptoms of oral cancer can include:
- red or red and white patches (oral leukoplakia) that appear on the lining of the mouth or the tongue
- sores and mouth ulcers that will not heal
- a sore throat or pain when swallowing
- a feeling that there is something lodged in the throat
- a painful tongue
- a hoarse voice
- difficulty moving the jaw or tongue
- neck or ear pain
- loose teeth
- swelling in the area that remains for more than three 3 weeks
- a lump in the mouth
- thickening of the lining of the mouth
- dentures that no longer fit correctly
Many of the early signs of mouth cancers can be hard to spot, so people may not notice any signs or symptoms when the cancer develops initially.
People who are more at risk of mouth cancer, such as those who smoke or drink excessively, should stay vigilant to any early signs. They should also schedule regular appointments with a doctor or dentist who can examine their mouth and identify any issues.
Symptoms:
The most common type of tongue cancer is called squamous cell carcinoma. Squamous cells are thin, flat cells that are present on the surface of the skin and the tongue, in the lining of the digestive and respiratory tracts, and in the lining of the mouth, throat, thyroid, and larynx.
The primary symptoms of tongue cancer are a painful tongue and the development of a sore on the tongue. Additional symptoms may include:
- pain in the jaw or throat
- pain when swallowing
- feeling as though something is catching in the throat
- a stiff tongue or jaw
- problems swallowing or chewing food
- a red or white patch forming on the lining of the mouth or tongue
- a tongue ulcer that will not heal
- numbness in the mouth
- bleeding from the tongue without reason
- a lump on the tongue that does not go away
The symptoms of tongue cancer are similar to those of other oral cancers, and they may also not be evident in the early stages of the disease.
It is also possible for people to have some of these symptoms without having tongue cancer or another type of oral cancer.
Doctors classify most cancer types into stages according to how much cancer is present and whether or not it has spread, or metastasized, to other parts of the body.
The classification system uses letters and numbers. The letter T indicates a tumor, and the letter N refers to neck lymph nodes. These letters each have a grading from 1–4 or 0–3 respectively.
People with a T1 tumor have the smallest grade of tumor, while people with a T4 tumor have the largest grade.
An N0 classification signifies that the tongue cancer has not spread to any neck lymph nodes. Tongue cancer that has spread to a significant number of lymph nodes has an N3 classification.
It is also possible to grade tongue cancer in the following ways:
- low grade
- moderate
- high grade
This grading denotes how aggressively the cancer is growing and how likely it is to spread to other parts of the body.
Experts do not fully understand why some people get tongue cancer. However, specific risk factors can increase a person’s likelihood of developing this disease.
Known risk factors include:
- smoking or chewing tobacco
- consuming alcohol in excess
- eating a diet low in fruit and vegetables and high in red meat or processed foods
- having a human papillomavirus (HPV) infection
- having a family history of tongue or mouth cancers
- having had previous cancers, particularly other squamous cell cancers
- Older men are the group most at risk of tongue cancer. Oral cancers are most common in those aged 50 or above.
- Smokers who also drink heavily are 15 times more likely to develop oral cancers than other people.
Additional risk factors include:
- gastroesophageal reflux disease (GERD)
- betel chewing, a common habit in Southeast Asia
- exposure to particular chemicals, including asbestos, sulfuric acid, and formaldehyde
- poor oral hygiene or other factors affecting the mouth, such as jagged teeth that cause irritation or dentures that do not fit properly
- medical history, including family medical history
- examining the tongue and mouth
- examining the lymph nodes to see if there is any enlargement
- biopsy
- CT or MRI
It is possible to cure tongue cancer, and the outlook is better for people who get an early diagnosis. People who have cancer that has not spread have a higher rate of survival.
The 5-year relative survival rate for tongue cancer is 78 percent before cancer spreads, compared with 36 percent once it has.
It is not possible to prevent tongue cancer from developing. However, if people notice any of the signs or symptoms of tongue cancer they should make an appointment with their doctor as soon as possible. The earlier a doctor can diagnose the disease, the sooner treatment can begin and the more favorable the outlook.
There are also lifestyle factors that people can control to minimize their risk of developing tongue cancer. These include:
- quitting smoking
- avoiding chewing tobacco products or betel
- limiting alcohol intake or avoiding it completely
- eating a varied, healthful diet that includes lots of fruit and vegetables
- practicing good dental hygiene by brushing and flossing regularly and attending regular dental appointments
- receiving a full course of the HPV vaccine
- practicing safe sex and using a dental dam for oral sex
People with tongue cancer will usually require surgery to remove the cancerous tissue. Surgeons can generally remove smaller tumors in a single operation.
Multiple and more complicated operations may be necessary if larger tumors are present or if the cancer has spread. The surgeon may also need to remove part of the tongue. If this is the case, they will attempt to rebuild the tongue using skin or tissue from other parts of the body.
Surgery that involves the removal of part or all of the tongue is called a glossectomy. Although doctors will attempt to minimize the damage to the mouth during the procedure, some side effects are inevitable.
Glossectomy can affect:
- speaking
- eating
- breathing
- swallowing
In addition to surgery, some people may have radiation or chemotherapy treatment to kill any cancerous cells that remain.
Saturday, February 1, 2020
Non-oncology drugs helps kill cancer cells
Research at Broad
Institute of MIT and Harvard and Dana-Farber Cancer Institute shows that many
non-oncology
drugs, including the drugs for diabetes, inflammation, alcoholism -- and
even for treating arthritis in dogs kill cancer cells in lab. The researchers analyzed
thousands of already developed drug compounds and found nearly 50 that have
previously unrecognized anti-cancer activity. The surprising findings, which
also revealed novel drug mechanisms and targets, suggest a possible way to
accelerate the development of new cancer drugs or repurpose existing drugs to
treat cancer.
The researchers tested
all the compounds in the Drug Repurposing Hub on 578 human
cancer cell lines from the Broad's Cancer Cell Line Encyclopedia (CCLE).
Using a molecular barcoding method known as PRISM, which was developed in the
Golub lab, the researchers tagged each cell line with a DNA barcode, allowing
them to pool several cell lines together in each dish and more quickly conduct
a larger experiment. The team then exposed each pool of barcoded cells to a
single compound from the repurposing library and measured the survival rate of
the cancer cells.
They found nearly 50
non-cancer drugs -- including those initially developed to lower cholesterol or
reduce inflammation -- that killed some cancer cells while leaving others
alone.
Some of the compounds
killed cancer cells in unexpected ways. "Most existing cancer
drugs work by blocking proteins, but we're finding that compounds can act
through other mechanisms," said Corsello. Some of the four-dozen drugs he
and his colleagues identified appear to act not by inhibiting a protein but by
activating a protein or stabilizing a protein-protein interaction. For example,
the team found that nearly a dozen non-oncology drugs killed cancer cells that
express a protein called PDE3A by stabilizing the interaction between PDE3A and
another protein called SLFN12 -- a previously unknown mechanism for some of
these drugs.
These unexpected drug
mechanisms were easier to find using the study's cell-based approach, which
measures cell survival, than through traditional non-cell-based high-throughput
screening methods, Corsello said.
Most of the non-oncology
drugs that killed cancer cells in the study did so by interacting with a
previously unrecognized molecular target. For example, the anti-inflammatory
drug tepoxalin, originally developed for use in people but approved for
treating osteoarthritis in dogs, killed cancer cells by hitting an unknown
target in cells that overexpress the protein MDR1, which commonly drives
resistance to chemotherapy
drugs.
The researchers were also
able to predict whether certain drugs could kill each cell line by looking at
the cell line's genomic features, such as mutations
and methylation levels, which were included in the CCLE database. This suggests
that these features could one day be used as biomarkers to identify patients
who will most likely benefit from certain drugs. For example, the alcohol
dependence drug disulfiram (Antabuse) killed cell lines carrying mutations that
cause depletion of metallothionein proteins. Compounds containing vanadium,
originally developed to treat diabetes, killed cancer cells that expressed the
sulfate transporter SLC26A2.
"The genomic
features gave us some initial hypotheses about how the drugs could be acting,
which we can then take back to study in the lab," said Corsello. "Our
understanding of how these drugs kill cancer cells gives us a starting point
for developing new therapies."
The researchers hope to
study the repurposing library compounds in more cancer
cell lines and to grow the hub to include even more compounds that have
been tested in humans. The team will also continue to analyze the trove of data
from this study, which have been shared openly (https://depmap.org)
with the scientific community, to better understand what's driving the
compounds' selective activity.
To explore more
interesting trends in cancer research, do join us at Paris, France, this July
1-2, 2020. For more info, PS: Cancer
Research 2020 | Brochure
Saturday, January 25, 2020
Cancer Research 2020
Here's the proceedings of Cancer Research 2019, https://www.pulsus.com/conference-abstracts/cancer-research-structural-biochemistry-2019-proceedings.html.
Join us at Cancer Research 2020, this July 1-2, 2020 in Paris, France. For more details, https://cancer.cmesociety.com/
Join us at Cancer Research 2020, this July 1-2, 2020 in Paris, France. For more details, https://cancer.cmesociety.com/
Monday, October 28, 2019
Cancer Summit 2019
Recent study shows, biomarkers help identify children
with cancer at risk for cognitive impairments. Explore more about cancer at: http://bit.ly/2K4sRl4
Saturday, October 5, 2019
Cancer Summit 2019
Trials show, circulating
tumor DNA detected through liquid biopsy, to be an independent prognostic
marker for identifying patients with colorectal cancer. Explore more oncology,
PS: https://cancer-oncology.pulsusconference.com/
Saturday, September 28, 2019
Saturday, September 7, 2019
Breakthrough therapy designation to capmatinib- Lung Cancer
The FDA granted
breakthrough therapy designation to capmatinib for first-line treatment of
metastatic MET exon 14 skipping-mutated non-small cell lung cancer.
MET mutations — identified
in approximately 4% of patients with NSCLC — are associated with poor
prognosis. The mutations, typically seen among older patients, can limit
treatment options.
No targeted therapies are approved to treat
MET exon 14 skipping-mutated NSCLC, an aggressive subtype of the disease.
Prior studies have shown
capmatinib (INC280, Novartis) — an investigational, oral MET inhibitor — to be
highly selective and potent in this setting, according to a Novartis-issued
press release. The FDA previously granted breakthrough therapy designation to
the agent for treatment of patients with this type of NSCLC who received prior
platinum-based chemotherapy.
“We look forward to working
with the FDA and global health authorities to bring capmatinib to patients who
currently have no available targeted therapy options,” John Tsai, MD, head
of global drug development and chief medical officer of Novartis, said in the
release.
Tuesday, August 27, 2019
Recent Trends in Oncology
Study
shows that de-intensified chemoradiotherapy regimen shows favorable clinical
outcomes among for HPV-associated oropharyngeal squamous cell carcinoma. Learn
more about oncology at: http://bit.ly/2Yxiv66
Thursday, August 22, 2019
Recent Trends in Oncology
Research
shows that patients with metastatic colorectal cancer who exercised regularly
achieved longer PFS than those who did not. Learn more about oncology at: http://bit.ly/2Yxiv66
Wednesday, August 21, 2019
Recent Trends in Oncology
Research
reveals that combo of palbociclib & cetuximab shows antitumor activity for platinum
or cetuximab resistant HPV unrelated head and neck squamous cell carcinoma. Explore
more about cancer at: http://bit.ly/2K4sRl4
Recent Trends in Oncology
Study
shows that breast cancer screening at a younger age prevent more than half of
all breast cancer-related deaths among childhood cancer survivors treated with
chest radiation. Learn more about oncology at: http://bit.ly/2Yxiv66
Monday, August 19, 2019
Recent Trends in Oncology
FDA
has approved fedratinib for intermediate-2 or high-risk primary or secondary
myelofibrosis. Learn more about oncology at: http://bit.ly/2Yxiv66
Recent Trends in Oncology
Applying
biomolecular engineering and synthetic biology techniques to develop “smarter
and stronger” T cells provides more effective and less toxic cancer therapy. Explore
more about cancer at: http://bit.ly/2K4sRl4
Friday, August 16, 2019
Recent Trends in Oncology
A
new study found that eating flavonoid rich foods reduce the risk of cancer. Explore
more about cancer at: http://bit.ly/2K4sRl4
Recent Trends in Oncology
FDA
granted approval to entrectinib for the treatment of adults and children with
cancers that harbor NTRK, gene fusion and for whom there are no effective
treatments. Learn more about oncology at: http://bit.ly/2Yxiv66
Wednesday, August 14, 2019
Recent Trends in Oncology
Study
suggests that replacing red meat with poultry lowers breast cancer risk. Explore
more about cancer at: http://bit.ly/2K4sRl4
Recent Trends in Oncology
Study
shows that abiraterone acetate and enzalutamide increase the risk for death
among old men with advanced prostate cancer and pre-existing cardiovascular
conditions. Know more about oncology at: http://bit.ly/2Yxiv66
Tuesday, August 13, 2019
Recent Trends in Oncology
Research
shows that cytoreductive surgery may be an effective treatment option for
specific subgroups of patients with primary central nervous system lymphoma. Explore
more about cancer at: http://bit.ly/2K4sRl4
Recent Trends in Oncology
Study
shows men with prostate cancer with +ve surgical margins, extracapsular
extension achieved longer biochemical RFS after radical prostatectomy with
adjuvant radiotherapy compared with only surgery. Know more Oncology at: http://bit.ly/2Yxiv66
Subscribe to:
Posts (Atom)



















